Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EIF2AK4 | Q9P2K8 | 9/20 | 0.34 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.33 |
| ▸ | IDH1 | O75874 | 1/20 | 0.31 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.31 |
| ▸ | CDK9 | P50750 | 1/20 | 0.31 |
| ▸ | SORD | Q00796 | 8/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25468524 | 0.91 | GRM1 (0.33) | EIF2AK4GRM1CCNT1CDK9SORD | |
| SCHEMBL25110555 | 0.89 | GRM1 (0.32) | EIF2AK4GRM1 | |
| SCHEMBL22794705 | 0.89 | SORD (0.34) | EIF2AK4IDH1CCNT1CDK9SORD | |
| SCHEMBL24514483 | 0.76 | ACACB (0.40) | IDH1SORD | |
| SCHEMBL25482372 | 0.76 | ACACB (0.40) | IDH1SORD | |
| SCHEMBL25110569 | 0.72 | SORD (0.31) | GRM1SORD | |
| SCHEMBL25109033 | 0.71 | SORD (0.30) | SORD | |
| SCHEMBL25468515 | 0.68 | GRM1 (0.31) | GRM1 | |
| SCHEMBL25110543 | 0.68 | GRM1 (0.31) | GRM1 | |
| SCHEMBL25110305 | 0.67 | ACACB (0.39) | SORD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230149549-A1 | SMARCA DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-05-18 | — | — | US | disclosed |
| WO-2022125804-A1 | SMARCA DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2022-06-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230149549-A1 | SMARCA DEGRADERS AND USES THEREOF | SMARCA1, SMARCB1, SMARCE1 | EIF2AK4 3735/4885GRM1 2687/4885IDH1 2952/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.